United States - English - NLM (National Library of Medicine)

allegis holdings, llc - naproxen (unii: 57y76r9atq) (naproxen - unii:57y76r9atq) - naproxen suspension is indicated for: the relief of the signs and symptoms of: - rheumatoid arthritis - osteoarthritis - ankylosing spondylitis - polyarticular juvenile idiopathic arthritis - tendonitis - bursitis - acute gout the management of: - pain - primary dysmenorrhea naproxen suspension is contraindicated in the following patients: - known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to naproxen or any components of the drug product [ see warnings and precautions (5.7, 5.9) ] - history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other nsaids. severe, sometimes fatal, anaphylactic reactions to nsaids have been reported in such patients [ see warnings and precautions (5.7, 5.8) ] - in the setting of coronary artery bypass graft (cabg) surgery [ see warnings and precautions (5.1) ] risk su

United States - English - NLM (National Library of Medicine)

allegis holdings, llc - dexamethasone (unii: 7s5i7g3jql) (dexamethasone - unii:7s5i7g3jql) - dexamethasone 1.5 mg

United States - English - NLM (National Library of Medicine)

allegis holdings, llc - trimethoprim hydrochloride (unii: 9xe000ou9b) (trimethoprim - unii:an164j8y0x) - trimethoprim 50 mg in 5 ml - primsol solution is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions listed below. for the treatment of acute otitis media due to susceptible strains of streptococcus pneumoniae and haemophilus influenzae . note: moraxella catarrhalis isolates were found consistently resistant to trimethoprim in vitro . therefore, when infection with moraxella catarrhalis is suspected, the use of alternative antimicrobial agents should be considered. primsol is not indicated for prophylactic or prolonged administration in otitis media at any age. for the treatment of initial episodes of uncomplicated urinary tract infections due to susceptible strains of the following organisms: escherichia coli, proteus mirabilis, klebsiella pneumoniae, enterobacter species and coagulase-negative staphylococcus species, including s. saprophyticus . cultures and s

United States - English - NLM (National Library of Medicine)

allegis holdings llc - adapalene (unii: 1l4806j2qf) (adapalene - unii:1l4806j2qf) - adapalene topical solution 0.1% is indicated for the topical treatment of acne vulgaris. adapalene topical solution 0.1% should not be administered to individuals who are hypersensitive to adapalene or any of the components in the vehicle solution.

United States - English - NLM (National Library of Medicine)

allegis holdings, llc - amoxicillin (unii: 804826j2hu) (amoxicillin anhydrous - unii:9em05410q9), clavulanate potassium (unii: q42omw3at8) (clavulanic acid - unii:23521w1s24) - augmentin is indicated for the treatment of infections in adults and pediatric patients, due to susceptible isolates of the designated bacteria in the conditions listed below: - lower respiratory tract infections - caused by beta‑lactamase–producing isolates of haemophilus influenzae and moraxella catarrhalis . - acute bacterial otitis media - caused by beta‑lactamase–producing isolates of h. influenzae and m. catarrhalis . - sinusitis - caused by beta‑lactamase–producing isolates of h. influenzae and m. catarrhalis . - skin and skin structure infections - caused by beta‑lactamase–producing isolates of staphylococcus aureus , escherichia coli , and klebsiella species. - urinary tract infections - caused by beta‑lactamase–producing isolates of e. coli , klebsiella species, and enterobacter species. limitations of use when susceptibility test results show susceptibility to amoxicillin, indicating no beta-lactamase production, augmentin should not be used. usage to reduce the development of drug‑resistant bacteria and maintain the effectiveness of augmentin and other antibacterial drugs, augmentin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. augmentin is contraindicated in patients with a history of serious hypersensitivity reactions (e.g., anaphylaxis or stevens-johnson syndrome) to amoxicillin, clavulanate or to other beta‑lactam antibacterial drugs (e.g., penicillins and cephalosporins). augmentin is contraindicated in patients with a previous history of cholestatic jaundice/hepatic dysfunction associated with augmentin. teratogenic effects : pregnancy category b. reproduction studies performed in pregnant rats and mice given augmentin (2:1 ratio formulation of amoxicillin:clavulanate) at oral doses up to 1200 mg/kg/day revealed no evidence of harm to the fetus due to augmentin. the amoxicillin doses in rats and mice (based on body surface area) were approximately 4 and 2 times the maximum recommended adult human oral dose (875 mg every 12 hours). for clavulanate, these dose multiples were approximately 9 and 4 times the maximum recommended adult human oral dose (125 mg every 8 hours). there are, however, no adequate and well-controlled studies in pregnant women. because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. oral ampicillin‑class antibacterials are poorly absorbed during labor. it is not known whether use of amoxicillin and clavulanate potassium in humans during labor or delivery has immediate or delayed adverse effects on the fetus, prolongs the duration of labor, or increases the likelihood of the necessity for an obstetrical intervention. amoxicillin has been shown to be excreted in human milk. amoxicillin and clavulanate potassium use by nursing mothers may lead to sensitization of infants. caution should be exercised when amoxicillin and clavulanate potassium is administered to a nursing woman. the safety and effectiveness of augmentin for oral suspension and chewable tablets have been established in pediatric patients. use of augmentin in pediatric patients is supported by evidence from studies of augmentin tablets in adults with additional data from a study of augmentin for oral suspension in pediatric patients aged 2 months to 12 years with acute otitis media [see clinical studies ( 14.2)] . because of incompletely developed renal function in neonates and young infants, the elimination of amoxicillin may be delayed; clavulanate elimination is unaltered in this age group. dosing of amoxicillin and clavulanate potassium should be modified in pediatric patients aged less than 12 weeks (less than 3 months) [see dosage and administration ( 2.3)]. of the 3,119 patients in an analysis of clinical studies of augmentin, 32% were greater than or equal to 65 years old, and 14% were greater than or equal to 75 years old. no overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. this drug is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with impaired renal function. because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. amoxicillin is primarily eliminated by the kidney and dosage adjustment is usually required in patients with severe renal impairment (gfr less than 30 ml/min). see patients with renal impairment [see dosage and administration ( 2.4)] for specific recommendations in patients with renal impairment.

United States - English - NLM (National Library of Medicine)

allegis pharmaceuticals, llc - .beta.-carotene (unii: 01yae03m7j) (.beta.-carotene - unii:01yae03m7j), ascorbic acid (unii: pq6ck8pd0r) (ascorbic acid - unii:pq6ck8pd0r), cholecalciferol (unii: 1c6v77qf41) (cholecalciferol - unii:1c6v77qf41), .alpha.-tocopherol acetate, dl- (unii: wr1wpi7ew8) (.alpha.-tocopherol, dl- - unii:7qwa1rio01), thiamine hydrochloride (unii: m572600e5p) (thiamine ion - unii:4abt0j945j), riboflavin (unii: tlm2976ofr) (riboflavin - unii:tlm2976ofr), niacinamide (unii: 25x51i8rd4) (niacinamide - unii:25x51i8r - .beta.-carotene 2100 [iu] - active fe™ is an oral prescription multi-vitamin/multi-mineral dietary supplement for the use in improving the nutritional status of patients with iron deficiency. 1 active fe™ is contraindicated in patients with a known hypersensitivity to any of the components of this product. hemolytic anemia, hemochromatosis and hemosiderosis are contraindications to iron therapy.

United States - English - NLM (National Library of Medicine)

allegis pharmaceuticals, llc - as a prescription topical skin care emulsion to manage and relieve the burning and itching experienced with various types of dermatoses, including atopic and allergic contact dermatitis. aladerm plus™ rx skin emulsion helps maintain a moist wound and skin environment, which is beneficial to the healing process. aladerm plus™ rx skin emulsion is contraindicated in persons with a known hypersensitivity to any of the components of the formulation.

United States - English - NLM (National Library of Medicine)

allegis pharmaceuticals, llc - brompheniramine maleate (unii: ixa7c9zn03) (brompheniramine - unii:h57g17p2fn) - brompheniramine maleate 4 mg in 1 ml

United States - English - NLM (National Library of Medicine)

allegis pharmaceuticals, llc - brompheniramine maleate (unii: ixa7c9zn03) (brompheniramine - unii:h57g17p2fn), phenylephrine hydrochloride (unii: 04ja59tnsj) (phenylephrine - unii:1ws297w6mv) - brompheniramine maleate 4 mg - temporarily relieves these symptoms due to the common cold, hay fever (allergic rhinitis) or other upper respiratory allergies: - runny nose - sneezing - itching of the nose or throat - itchy, watery eyes - nasal congestion - reduces swelling of nasal passages

United States - English - NLM (National Library of Medicine)

allegis pharmaceuticals, llc - brompheniramine maleate (unii: ixa7c9zn03) (brompheniramine - unii:h57g17p2fn), phenylephrine hydrochloride (unii: 04ja59tnsj) (phenylephrine - unii:1ws297w6mv) - brompheniramine maleate 4 mg - temporarily relieves these symptoms due to the common cold, hay fever (allergic rhinitis) or other upper respiratory allergies: - runny nose - sneezing - itching of the nose or throat - itchy, watery eyes - nasal congestion - reduces swelling of nasal passages